NCT07323329

Growth Hormone and Dehydroepiandrosterone Role in Vitro Fertilization

Growth Hormone and Dehydroepiandrosterone Effect on Poor Ovarian Reserve Patients During in Vitro Fertilization

• Status: Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 165 (estimated)
• Sponsor: Beni-Suef University · Academic / Other
• Sex: Female
• Age: 18 Years – 35 Years
• Healthy volunteers: Not accepted

Summary

The goal of this study is to evaluate the role of Somatropin and Dehydroepiandrosterone (DHEA) on ovarian reserve parameters and intracytoplasmic sperm injection (ICSI) outcome in poor ovarian responder. The main question it aims to answer is: Which intervention is more effective in increasing number and size of follicles? Participants will be followed 1 month before starting induction in growth hormone and 12 weeks for DHEA and through intracytoplasmic sperm injection (ICSI) cycle.

Conditions

• Infertility
• Infertility (IVF Patients)

Interventions

Type	Name	Description
DRUG	Somatropin (4IU for 1 month) plus, folic acid 400 mcg per day.	Patients will receive Somatropin (4IU for 1 month)1 S.C injection every 3 days for at least 1 month plus, folic acid 400 mcg per day.
DRUG	DHEA plus folic acid 400mcg per day	Patients will receive DHEA 50 mg twice per day for 12 weeks plus folic acid 400mcg per day
DIETARY_SUPPLEMENT	control group	Patients will receive folic acid 400 mcg per day

Timeline

• Start date: 2025-10-10
• Primary completion: 2026-10-15
• Completion: 2026-11-12
• First posted: 2026-01-07
• Last updated: 2026-01-07

Locations

1 site across 1 country: Egypt